Abbott Cardiovascular Systems, Inc.

Advanced Cardiovascular Systems, Inc.

Gene Michal

John Joseph Stankus

Shubhayu Basu

Mikael Trollsas

Syed F Hossainy

Michael H Ngo

Jinping Wan

Florian Niklas Ludwig

Stephen D Pacetti

Ni Ding

Jeong Soo Lee

Paul M Consigny

Charles David Claude

Florian Ludwig

Evgenia Mandrusov

Richard T Thornton

Connie S Kwok

Jihong Qu

Gabriel Asongwe

Ken Bueche

Mary B Michaels

Joseph J Sciacca

John Eric Henckel

Sophia W Liao

Daniel Wiegand

Fidel Albert Urrabazo

Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael's addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other component is selected from collagen, collagen-laminin, poly-1-lysine, and fibrin. The bioscaffolding may further include an alginate component. The bioscaffoldings may have biofunctional groups such as angiogenic factors and stem cell homing factors bound to the collagen, collagen-laminin, poly-1-lysine, or fibrinogen hydrogel component. In particular, the biofunctional groups may be PR11, PR39, VEGF, bFGF, a polyarginine/DNA plasmid complex, or a DNA/polyethyleneimine (PEI) complex. Additionally, the hydrogel components may be injected into the infarct region along with stem cells and microspheres containing stem cell homing factors. The bioscaffolding may be formed on a stent or a cardiac medical device.

Hydrogel bioscaffoldings and biomedical device coatings

Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.

Methods and compositions for treating tissue using silk proteins

A bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture. A treatment agent, such as a cell type or a growth factor, can be added to either the first mixture or the second mixture. In some embodiments, the treatment agent is not added to either mixture. The first mixture can be co-injected with the second mixture to form a bioscaffolding in an infarct region for treatment thereof.

Modified two-component gelation systems, methods of use and methods of manufacture

Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems.

Intracoronary device and method of use thereof

The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy.

Cytocompatible alginate gels

A carbon coating on a stent having a bioactive agent covalently attached thereto and methods of making the same are described. The covalent attachment may be achieved via a photo-reactive chemical or a thermo-reactive chemical. In some embodiments, the carbon coating includes a diamond-like material. The bioactive agent may be heparin or superoxide dismutase enzyme or a mimetic thereof.

Carbon coating on an implantable device

A coated stent is provided including a coating composed of one or more co-polymers of ethylene with carboxylic acid wherein the carboxylic acid co-monomer content is 5-50 wt %.

Ethylene-carboxyl copolymers as drug delivery matrices

A coated stent is provided including a coating comprising one or more co-polymers of ethylene with carboxylic acid wherein the carboxylic acid co-monomer content is 5-50 wt%.

Growing community of inventors

San Francisco, CA, United States of America

Gene Michal